[{"id":"c6ca9580-1b4f-4786-bd6d-7874e5540e9b","acronym":"GIST","url":"https://clinicaltrials.gov/study/NCT05661643","created_at":"2022-12-22T14:58:40.763Z","updated_at":"2024-07-02T16:35:14.738Z","phase":"Phase 2","brief_title":"The Efficacy and Safety of Temozolomide in SDH-deficient GIST","source_id_and_acronym":"NCT05661643 - GIST","lead_sponsor":"Asan Medical Center","biomarkers":" KIT • PDGFRA • ANO1","pipe":"","alterations":" ","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 06/28/2023","start_date":" 06/28/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-03-15"},{"id":"afe5eda5-b0b2-4528-9023-e2c1d7118027","acronym":"","url":"https://clinicaltrials.gov/study/NCT05905887","created_at":"2023-06-15T17:08:41.962Z","updated_at":"2024-07-02T16:35:17.151Z","phase":"Phase 2","brief_title":"Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor","source_id_and_acronym":"NCT05905887","lead_sponsor":"Asan Medical Center","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" KIT mutation","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • imatinib • sunitinib • AiTan (rivoceranib) • Stivarga (regorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 09/06/2023","start_date":" 09/06/2023","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-02-28"},{"id":"0eefbaf9-a4ea-454b-868c-1b99280a8dd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01541709","created_at":"2021-01-18T06:30:56.005Z","updated_at":"2024-07-02T16:35:24.757Z","phase":"Phase 2","brief_title":"Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI","source_id_and_acronym":"NCT01541709","lead_sponsor":"Asan Medical Center","biomarkers":" KIT • ANO1","pipe":" | ","alterations":" KIT mutation • KIT exon 9 mutation","tags":["KIT • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT exon 9 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 03/01/2012","start_date":" 03/01/2012","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-01-01"},{"id":"4c2f1c18-6e61-4a09-9dd2-0ccca96142b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03944304","created_at":"2021-01-18T19:25:15.034Z","updated_at":"2024-07-02T16:35:24.855Z","phase":"Phase 2","brief_title":"Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.","source_id_and_acronym":"NCT03944304","lead_sponsor":"Asan Medical Center","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" KIT mutation","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • imatinib • sunitinib • Stivarga (regorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 05/27/2019","start_date":" 05/27/2019","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-01-01"},{"id":"ff971a31-4620-40ce-aa35-33a25eb28431","acronym":"","url":"https://clinicaltrials.gov/study/NCT02413736","created_at":"2021-01-18T11:31:48.616Z","updated_at":"2024-07-02T16:35:29.677Z","phase":"Phase 3","brief_title":"Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST","source_id_and_acronym":"NCT02413736","lead_sponsor":"Heikki Joensuu","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" KIT mutation • PDGFRA mutation","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 255","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2033","study_completion_date":" 05/01/2033","last_update_posted":"2023-11-09"},{"id":"9311c6a1-8eb7-4bef-bf44-cda43d3d097a","acronym":"ALT GIST","url":"https://clinicaltrials.gov/study/NCT02365441","created_at":"2021-01-18T11:15:45.915Z","updated_at":"2024-07-02T16:35:43.660Z","phase":"Phase 2","brief_title":"A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)","source_id_and_acronym":"NCT02365441 - ALT GIST","lead_sponsor":"Australasian Gastro-Intestinal Trials Group","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" PDGFRA mutation","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • Stivarga (regorafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 06/30/2015","start_date":" 06/30/2015","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2023-07-07"},{"id":"9dc25681-6ec7-49c7-b682-824ec8a0c088","acronym":"","url":"https://clinicaltrials.gov/study/NCT05385549","created_at":"2022-05-23T16:54:10.153Z","updated_at":"2024-07-02T16:35:53.625Z","phase":"Phase 2","brief_title":"5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk","source_id_and_acronym":"NCT05385549","lead_sponsor":"Asan Medical Center","biomarkers":" KIT • ANO1","pipe":" | ","alterations":" KIT mutation","tags":["KIT • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 09/07/2022","start_date":" 09/07/2022","primary_txt":" Primary completion: 04/30/2030","primary_completion_date":" 04/30/2030","study_txt":" Completion: 04/30/2030","study_completion_date":" 04/30/2030","last_update_posted":"2023-03-09"},{"id":"ea5d6031-d473-42c0-8a28-91a62279cacc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03609424","created_at":"2021-01-18T17:44:34.659Z","updated_at":"2025-02-25T15:43:08.795Z","phase":"Phase 1/2","brief_title":"PDR001 Plus Imatinib for Metastatic or Unresectable GIST","source_id_and_acronym":"NCT03609424","lead_sponsor":"Asan Medical Center","biomarkers":" KIT • CD8 • PD-1 • LAG3 • ANO1 • MSR1","pipe":" | ","alterations":" KIT mutation • KIT exon 9 mutation • KIT exon 13 mutation","tags":["KIT • CD8 • PD-1 • LAG3 • ANO1 • MSR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT exon 9 mutation • KIT exon 13 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • sunitinib • Stivarga (regorafenib) • spartalizumab (PDR001)"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 02/14/2019","start_date":" 02/14/2019","primary_txt":" Primary completion: 11/11/2021","primary_completion_date":" 11/11/2021","study_txt":" Completion: 11/11/2021","study_completion_date":" 11/11/2021","last_update_posted":"2023-01-02"},{"id":"b933d773-32a4-4ee6-ab9c-3b71b74aefa7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05464875","created_at":"2022-07-19T14:54:36.704Z","updated_at":"2024-07-02T16:36:07.154Z","phase":"","brief_title":"A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors","source_id_and_acronym":"NCT05464875","lead_sponsor":"Xinhua Zhang, MD","biomarkers":" ANO1","pipe":"","alterations":" ","tags":["ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 07/09/2022","start_date":" 07/09/2022","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 08/31/2024","study_completion_date":" 08/31/2024","last_update_posted":"2022-07-19"},{"id":"9b88117e-7f14-42f3-b2bd-24fb2ea08987","acronym":"","url":"https://clinicaltrials.gov/study/NCT05461664","created_at":"2022-07-18T14:01:34.811Z","updated_at":"2024-07-02T16:36:07.233Z","phase":"","brief_title":"Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA","source_id_and_acronym":"NCT05461664","lead_sponsor":"Xinhua Zhang, MD","biomarkers":" ANO1","pipe":"","alterations":" ","tags":["ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 07/10/2022","start_date":" 07/10/2022","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 08/31/2024","study_completion_date":" 08/31/2024","last_update_posted":"2022-07-18"},{"id":"81a8c9c6-1d7c-4f73-860b-081e300b48a3","acronym":"TRANSGIST","url":"https://clinicaltrials.gov/study/NCT04825470","created_at":"2021-04-01T16:52:24.802Z","updated_at":"2024-07-02T16:36:15.578Z","phase":"","brief_title":"Liver Transplantation for Unresectable GIST Liver Metastases","source_id_and_acronym":"NCT04825470 - TRANSGIST","lead_sponsor":"Hospital Universitario Virgen de la Arrixaca","biomarkers":" KIT • CD34 • ANO1","pipe":"","alterations":" ","tags":["KIT • CD34 • ANO1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 05/01/2022","start_date":" 05/01/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2022-03-11"},{"id":"057c88c5-edbb-41d4-a61e-3b9b94a6ba2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02924714","created_at":"2021-01-18T14:21:47.438Z","updated_at":"2025-02-25T16:31:00.901Z","phase":"","brief_title":"SSG XXV: The Stop-GIST Trial; Discontinuation of Imatinib in Patients With Oligo-metastatic GIST","source_id_and_acronym":"NCT02924714","lead_sponsor":"Oslo University Hospital","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" PDGFRA mutation","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Suspended","enrollment":" Enrollment 31","initiation":"Initiation: 01/01/2017","start_date":" 01/01/2017","primary_txt":" Primary completion: 11/01/2022","primary_completion_date":" 11/01/2022","study_txt":" Completion: 11/01/2022","study_completion_date":" 11/01/2022","last_update_posted":"2022-02-18"},{"id":"85d16f1e-1c34-4a39-a9c5-34455f313731","acronym":"","url":"https://clinicaltrials.gov/study/NCT05132738","created_at":"2021-11-24T18:55:38.113Z","updated_at":"2024-07-02T16:36:20.274Z","phase":"","brief_title":"Ripretinib Used for Resectable Metastatic GIST After Failure of Imatinib Therapy","source_id_and_acronym":"NCT05132738","lead_sponsor":"RenJi Hospital","biomarkers":" KIT • ANO1","pipe":"","alterations":" ","tags":["KIT • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • Qinlock (ripretinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 08/01/2021","start_date":" 08/01/2021","primary_txt":" Primary completion: 11/30/2023","primary_completion_date":" 11/30/2023","study_txt":" Completion: 11/30/2023","study_completion_date":" 11/30/2023","last_update_posted":"2021-11-24"},{"id":"65aa546b-6373-4d3e-bd0b-ba34a643210e","acronym":"ZJGIST-01","url":"https://clinicaltrials.gov/study/NCT04933669","created_at":"2021-06-22T15:52:32.553Z","updated_at":"2024-07-02T16:36:23.163Z","phase":"Phase 2","brief_title":"Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors","source_id_and_acronym":"NCT04933669 - ZJGIST-01","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" KIT mutation • KIT exon 11 mutation • KIT exon 9 mutation • KIT positive • PDGFRA mutation • KIT exon 13 mutation • KIT exon 17 mutation","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT exon 11 mutation • KIT exon 9 mutation • KIT positive • PDGFRA mutation • KIT exon 13 mutation • KIT exon 17 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Recruiting","enrollment":" Enrollment 122","initiation":"Initiation: 09/07/2021","start_date":" 09/07/2021","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2021-10-12"},{"id":"bbe275ad-6be5-4313-a449-5847e6c48405","acronym":"CYCLIGIST","url":"https://clinicaltrials.gov/study/NCT01907607","created_at":"2021-01-18T08:35:33.854Z","updated_at":"2024-07-02T16:36:35.901Z","phase":"Phase 2","brief_title":"Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib","source_id_and_acronym":"NCT01907607 - CYCLIGIST","lead_sponsor":"Institut Bergonié","biomarkers":" KIT • CDKN2A • PDGFRA • ANO1","pipe":" | ","alterations":" CDKN2A deletion • PDGFRA mutation","tags":["KIT • CDKN2A • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A deletion • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • imatinib • sunitinib"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 02/01/2014","start_date":" 02/01/2014","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 02/01/2019","study_completion_date":" 02/01/2019","last_update_posted":"2021-01-20"},{"id":"d4e51655-c126-480a-abc9-777a3469bb93","acronym":"","url":"https://clinicaltrials.gov/study/NCT01440959","created_at":"2021-01-18T05:58:17.058Z","updated_at":"2024-07-02T16:36:51.163Z","phase":"Phase 2","brief_title":"Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258","source_id_and_acronym":"NCT01440959","lead_sponsor":"Asan Medical Center","biomarkers":" KIT • ANO1","pipe":" | ","alterations":" KIT mutation","tags":["KIT • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • sunitinib • dovitinib (TKI258)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 03/01/2013","primary_completion_date":" 03/01/2013","study_txt":" Completion: 03/01/2013","study_completion_date":" 03/01/2013","last_update_posted":"2020-01-18"},{"id":"6df23204-0048-41ea-9be6-a65c66fc3354","acronym":"","url":"https://clinicaltrials.gov/study/NCT02889328","created_at":"2021-01-18T14:10:45.547Z","updated_at":"2024-07-02T16:36:51.530Z","phase":"Phase 2","brief_title":"Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs","source_id_and_acronym":"NCT02889328","lead_sponsor":"Asan Medical Center","biomarkers":" KIT • ANO1","pipe":" | ","alterations":" KIT mutation","tags":["KIT • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • sunitinib • Stivarga (regorafenib)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 09/01/2016","start_date":" 09/01/2016","primary_txt":" Primary completion: 08/09/2017","primary_completion_date":" 08/09/2017","study_txt":" Completion: 01/01/2018","study_completion_date":" 01/01/2018","last_update_posted":"2020-01-09"},{"id":"0ab07a7b-9126-4248-8944-9c250490d370","acronym":"","url":"https://clinicaltrials.gov/study/NCT03440515","created_at":"2021-01-18T16:58:09.427Z","updated_at":"2024-07-02T16:36:51.796Z","phase":"Phase 2","brief_title":"Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor","source_id_and_acronym":"NCT03440515","lead_sponsor":"Asan Medical Center","biomarkers":" KIT • ANO1","pipe":" | ","alterations":" KIT mutation","tags":["KIT • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • prednisone"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 08/01/2014","start_date":" 08/01/2014","primary_txt":" Primary completion: 06/01/2017","primary_completion_date":" 06/01/2017","study_txt":" Completion: 06/01/2017","study_completion_date":" 06/01/2017","last_update_posted":"2020-01-07"},{"id":"e88ae05d-deea-4812-9248-f4f2961e66e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02607332","created_at":"2021-01-18T12:39:51.753Z","updated_at":"2024-07-02T16:36:51.800Z","phase":"Phase 2","brief_title":"Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib","source_id_and_acronym":"NCT02607332","lead_sponsor":"Asan Medical Center","biomarkers":" KIT • ANO1","pipe":" | ","alterations":" KIT mutation","tags":["KIT • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • imatinib • sunitinib"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 01/01/2018","primary_completion_date":" 01/01/2018","study_txt":" Completion: 01/01/2018","study_completion_date":" 01/01/2018","last_update_posted":"2020-01-07"},{"id":"57c81b9c-1589-48e6-af8a-b8850f1fe404","acronym":"","url":"https://clinicaltrials.gov/study/NCT03923400","created_at":"2021-01-18T19:18:05.505Z","updated_at":"2024-07-02T16:37:00.373Z","phase":"","brief_title":"Jejunoileal vs Gastric GIST in the Era of Imatinib.","source_id_and_acronym":"NCT03923400","lead_sponsor":"Hospital Universitario Virgen de la Arrixaca","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" KIT mutation • KIT positive • PDGFRA mutation • KIT expression","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT positive • PDGFRA mutation • KIT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Completed","enrollment":" Enrollment 77","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 01/31/2017","primary_completion_date":" 01/31/2017","study_txt":" Completion: 01/31/2017","study_completion_date":" 01/31/2017","last_update_posted":"2019-04-22"},{"id":"025ca360-2cf4-403e-9a64-782a5fc251ea","acronym":"PAGIST","url":"https://clinicaltrials.gov/study/NCT01524848","created_at":"2021-01-18T06:25:31.909Z","updated_at":"2025-02-25T13:17:28.808Z","phase":"Phase 2","brief_title":"Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib","source_id_and_acronym":"NCT01524848 - PAGIST","lead_sponsor":"Scandinavian Sarcoma Group","biomarkers":" KIT • ANO1","pipe":" | ","alterations":" KIT mutation • KIT positive","tags":["KIT • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • sunitinib • pazopanib"],"overall_status":"Completed","enrollment":" Enrollment 72","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 01/01/2015","primary_completion_date":" 01/01/2015","study_txt":" Completion: 11/01/2016","study_completion_date":" 11/01/2016","last_update_posted":"2017-05-10"},{"id":"05655b81-f61f-4430-a051-3fbad631a8f5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02776878","created_at":"2021-01-18T13:37:00.696Z","updated_at":"2024-07-02T16:37:32.017Z","phase":"","brief_title":"A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST","source_id_and_acronym":"NCT02776878","lead_sponsor":"Peking University Cancer Hospital \u0026 Institute","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" KIT exon 11 mutation • PDGFRA mutation • KIT wild-type • PDGFRA exon 18 mutation • PDGFR wild-type","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT exon 11 mutation • PDGFRA mutation • KIT wild-type • PDGFRA exon 18 mutation • PDGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Unknown status","enrollment":" Enrollment 57","initiation":"Initiation: 05/01/2016","start_date":" 05/01/2016","primary_txt":" Primary completion: 10/01/2017","primary_completion_date":" 10/01/2017","study_txt":" Completion: 05/01/2018","study_completion_date":" 05/01/2018","last_update_posted":"2016-05-18"},{"id":"04ac85c8-bcaa-421c-a636-5b035a66e79d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01478373","created_at":"2021-01-18T06:10:09.121Z","updated_at":"2024-07-02T16:37:32.504Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib","source_id_and_acronym":"NCT01478373","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" PDGFRA mutation","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • dovitinib (TKI258)"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 01/01/2012","start_date":" 01/01/2012","primary_txt":" Primary completion: 07/01/2014","primary_completion_date":" 07/01/2014","study_txt":" Completion: 07/01/2014","study_completion_date":" 07/01/2014","last_update_posted":"2016-04-27"}]